Literature DB >> 11298127

Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes.

K Migita1, S Yamasaki, K Shibatomi, H Ida, M Kita, A Kawakami, K Eguchi.   

Abstract

Secondary amyloidosis (AA amyloidosis) is a systemic disease characterized by the extracellular tissue deposition of insoluble amyloid A (AA) protein. Aberrant metabolism of serum amyloid A (SAA) by macrophages is only one of many putative mechanisms which may be important in AA amyloidogenesis. In this study, we investigated the effects of cytokines on human monocyte-mediated SAA proteolysis. Human peripheral blood mononuclear cells (PBMC) or CD14(+) monocytes were cultured with SAA, and the culture supernatants were then subjected to anti-SAA immunoblot. CD14(+) monocytes degraded SAA completely. Whereas, when CD14(+) monocytes were pretreated with IL-1 beta or IFN-gamma, increasing amounts of SAA-related derivatives were detected in culture supernatants. These findings suggest that activation of monocytes by IL-1 beta or IFN-gamma hampers the proteolysis of a precursor protein and leads to a partial degradation of SAA. This down-regulated proteolysis of SAA protein by cytokine-stimulated monocytes may play a role in the mechanism of AA amyloid formation as well as its removal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298127      PMCID: PMC1906015          DOI: 10.1046/j.1365-2249.2001.01472.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Heparan sulfate proteoglycans in amyloidogenesis: an epiphenomenon, a unique factor, or the tip of a more fundamental process?

Authors:  R Kisilevsky
Journal:  Lab Invest       Date:  1990-11       Impact factor: 5.662

Review 2.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

3.  Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits.

Authors:  C Tape; R Tan; M Nesheim; R Kisilevsky
Journal:  Scand J Immunol       Date:  1988-09       Impact factor: 3.487

Review 4.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein.

Authors:  D M Steel; A S Whitehead
Journal:  Immunol Today       Date:  1994-02

5.  Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin.

Authors:  T Yamada; J Liepnieks; M D Benson; B Kluve-Beckerman
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

6.  Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Authors:  M B Pepys; T W Rademacher; S Amatayakul-Chantler; P Williams; G E Noble; W L Hutchinson; P N Hawkins; S R Nelson; J R Gallimore; J Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

7.  Isolation and partial characterization of SAA-an amyloid-related protein from human serum.

Authors:  C J Rosenthal; E C Franklin; B Frangione; J Greenspan
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

8.  Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone.

Authors:  J W Smith; T L McDonald
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

9.  In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation.

Authors:  T Yamada; B Kluve-Beckerman; J J Liepnieks; M D Benson
Journal:  Scand J Immunol       Date:  1995-06       Impact factor: 3.487

10.  Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes.

Authors:  G Lavie; D Zucker-Franklin; E C Franklin
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  6 in total

1.  Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition.

Authors:  C Poitou; N Viguerie; R Cancello; R De Matteis; S Cinti; V Stich; C Coussieu; E Gauthier; M Courtine; J D Zucker; G S Barsh; W Saris; P Bruneval; A Basdevant; D Langin; K Clément
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

2.  Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications.

Authors:  Xuefeng B Ling; Jane L Park; Tanya Carroll; Khoa D Nguyen; Kenneth Lau; Claudia Macaubas; Edward Chen; Tzielan Lee; Christy Sandborg; Diana Milojevic; John T Kanegaye; Susanna Gao; Jane Burns; James Schilling; Elizabeth D Mellins
Journal:  Proteomics       Date:  2010-11-23       Impact factor: 3.984

3.  Long-term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice.

Authors:  N Muhammad; T Murakami; Y Inoshima; N Ishiguro
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

4.  Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.

Authors:  C Röcken; R Menard; F Bühling; S Vöckler; J Raynes; B Stix; S Krüger; A Roessner; T Kähne
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

5.  The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy.

Authors:  Alper Sevimli; Deniz Misirlioğlu; Artay Yağci; Aziz Bülbül; Arzu Yilmaztepe; Korhan Altunbas
Journal:  Vet Res Commun       Date:  2008-07-09       Impact factor: 2.459

6.  The Hidden Cost of Untreated Paragangliomas of the Head and Neck: Systemic Reactive (AA) Amyloidosis.

Authors:  Erkan Dervisoglu; Murat Ozturk; Mehmet Tuncay; Gulhatun Kilic Dervisoglu; Yesim Gurbuz; Serhan Derin
Journal:  Case Rep Nephrol       Date:  2015-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.